The field of bovine immunology has made significant strides in understanding the biology and function of T cells, which are crucial players in shaping ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced ...

DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, ...

Why can the human immune system often remember a vaccination for a whole lifetime? Researchers at ...

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...

Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.

ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA)ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi ...